Evidence map›Paper›PMID 38394783›Full record

Trial reportJournal of the National Comprehensive Cancer Network : JNCCN2024

Group Coping Intervention in Patients With Chronic Graft-Versus-Host Disease: A Pilot Randomized Clinical Trial.

Ashley M Nelson, Daniel Yang, Annemarie D Jagielo, Jennifer D'Alotto, Cathleen Poliquin, Dustin J Rabideau, Katherine G Cronin, Richard A Newcomb, Yi-Bin Chen, Zachariah DeFilipp and 3 more

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of the National Comprehensive Cancer Network : JNCCN, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 3 citations in OpenAlex.

  1. Trial
  2. Trial
  3. "They knew the same struggles": perceptions of a group coping skills intervention in patients with chronic graft-versus-host disease.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Trial
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Ashley M Nelson1Massachusetts General Hospital, Boston, Massachusetts.
Daniel Yang1Massachusetts General Hospital, Boston, Massachusetts.
Annemarie D Jagielo1Massachusetts General Hospital, Boston, Massachusetts.
Jennifer D'Alotto1Massachusetts General Hospital, Boston, Massachusetts.
Cathleen Poliquin1Massachusetts General Hospital, Boston, Massachusetts.
Dustin J Rabideau1Massachusetts General Hospital, Boston, Massachusetts.
Katherine G Cronin1Massachusetts General Hospital, Boston, Massachusetts.
Richard A Newcomb1Massachusetts General Hospital, Boston, Massachusetts.
Yi-Bin Chen1Massachusetts General Hospital, Boston, Massachusetts.
Zachariah DeFilipp1Massachusetts General Hospital, Boston, Massachusetts.
Joseph A Greer1Massachusetts General Hospital, Boston, Massachusetts.
Areej El-Jawahri1Massachusetts General Hospital, Boston, Massachusetts.
Lara Traeger1Massachusetts General Hospital, Boston, Massachusetts.
Massachusetts General Hospital · USHarvard University · US

Funding

Training in Oncology Population Sciences (TOPS)T32CA092203 · NCI · DANA-FARBER CANCER INST · PI Nancy L Keating, JENNIFER W MACK · 2018 to 2026
$3.7M
Reducing Persistent Fatigue Following Hematopoietic Stem Cell TransplantationK23HL159328 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI NELSON, ASHLEY · 2021 to 2025
$870k
NCI NIH HHS T32 CA092203NHLBI NIH HHS K23 HL159328
6 · The paper itself

Abstract

backgroundMore than half the long-term survivors of allogeneic hematopoietic cell transplantation develop chronic graft-versus-host disease (GVHD), a debilitating inflammatory syndrome. Supportive interventions to assist survivors in coping with chronic GVHD are critically needed. PATIENTS AND

methodsWe conducted a pilot randomized clinical trial of a multidisciplinary group intervention (Horizons Program; n=39) versus minimally enhanced usual care (n=41) for patients with moderate or severe chronic GVHD. Horizons participants received 8 weekly sessions about GVHD and coping co-led by a transplant clinician and a behavioral health expert via a secure videoconferencing platform. Participants completed the following surveys before randomization, at 10 weeks, and at 18 weeks: Functional Assessment of Cancer Therapy-Bone Marrow Transplant Scale (FACT-BMT) for quality of life (QoL), Lee Symptom Scale for symptom burden, and Hospital Anxiety and Depression Scale-Depression Symptoms (HADS) for mood. The primary endpoint was feasibility (≥50% enrollment, ≥80% attendance in half the sessions for the Horizons arm only, and ≥80% retention). We also explored preliminary efficacy of the Horizons intervention on changes in patient-reported outcomes with linear mixed effects models and estimates of effect size at 10 weeks.

resultsWe enrolled and registered 80 (67.2%) of 119 eligible patients (mean age, 62 years; 48.8% female). Of the participants in the Horizons Program, 84.6% attended at least half the sessions. Of registered participants, 91.3% completed assessment follow-ups (Horizons, 35/39 [89.7%]; minimally enhanced usual care, 38/41 [92.7%]). Horizons participants reported improvements in QoL (b = 2.24; d=0.53), anxiety symptoms (b = -0.10; d=0.34), and depression symptoms (b = -0.71; d=0.44) compared with participants who received minimally enhanced usual care.

conclusionsParticipation in a multidisciplinary group intervention study was feasible for patients with chronic GVHD, with promising signals for improving QoL and mood. A full-scale efficacy trial is needed to confirm effects on patient-reported outcomes.

Indexed as

Bronchiolitis Obliterans SyndromeGraft vs Host DiseaseAdaptation, PsychologicalFemaleHumansMaleMiddle AgedPilot ProjectsQuality of LifeFeasibility StudiesGraft vs Host DiseasePsychosocial InterventionQuality of LifeRandomized Controlled Trial

Identifiers

PMID38394783
PMCPMC11112519
OpenAlexW4392092946

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.